Novartis' Alcon buys PowerVision

Mar 18, 2019

Alcon, Novartis' eye care division, has acquired PowerVision, a privately-held medical device development company focused on creating fluid-based intraocular lens implants.

The $ 285 million acquisition furthers Alcon's commitment to bring this innovative, accommodating lens to cataract patients throughout the world.

While most presbyopia-correcting intraocular lenses use a multifocal design that distributes light between different focal points, PowerVision's groundbreaking fluid-based design creates a continuously variable monofocal lens, utilizing the natural contraction of the eye's muscles. This technology allows the patient to actively focus on objects, just as the natural crystalline lens does in a youthful eye, providing patients with a natural, continuous range of vision.

Commercial availability of Texas-based PowerVision's IOL technology is pending significant additional development and clinical trials of the intraocular lens.

Read the press release.

Want to get content like this in your inbox?  Subscribe to our eNewsletter here!